Observational studyMedical mycology2023
Neonatal invasive candidiasis in low- and middle-income countries: Data from the NeoOBS study.
Observational study in Medical mycology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Antifungal therapy for newborn infants with invasive fungal infection.The Cochrane database of systematic reviews · 2026Pooled it
- Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries.Mycopathologia · 2024Pooled it
- Neonatal candidemia over seven years: Epidemiological trends, risk factors, and outcome associations with Paed-EQUAL Candida score adherence.European journal of pediatrics · 2026Article
- Neonatal Candidemia: Clinical Characteristics and Predictors of 28-Day Mortality.Journal of fungi (Basel, Switzerland) · 2026Article
- Clinical Utility of the Paed-EQUAL Candida Score in Paediatric Candidemia: A Real-World Cohort Study.Mycoses · 2026Observational
- High burden of Candida blankii (syn.Tardiomyces blankii) bloodstream infections among neonates in an intensive care unit in Bangladesh.BMC infectious diseases · 2026Article
- Neonatal Candidemia in Latin America: Trends, Resistance, and Prevention Strategies (2008-2025).Journal of fungi (Basel, Switzerland) · 2026Review
- The Gut as a Source of Infection for Fungal Pathogens: Increased Fecal Candida albicans Precedes Onset of Candida Late-Onset Sepsis in Very Preterm Infants.The Journal of infectious diseases · 2026Article
- Irrational and Inappropriate Use of Antifungals in the NICU: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Hemodynamic profile of neonatal fungal sepsis with insights into the disease spectrum: a retrospective study.Frontiers in pediatrics · 2026Article
- Antifungal Stewardship in the Pediatric Intensive Care Unit: Time is of the Essence.Infection and drug resistance · 2026Review
- First case of a humanASM case reports · 2026Article
- Neonatal fungemia: a case series highlighting the threat posed by non-albicans Candida (NAC) species and a yeast-like filamentous fungus.BMC infectious diseases · 2025Article
- The accuracy of the Candida ScoreAnnals of medicine · 2025Article
- A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand.Scientific reports · 2025Article
- Trends in Pediatric Invasive Candidiasis: Shifting Species Distribution and Improving Outcomes.Mycopathologia · 2025Article
- Article
- Shorter or biomarker-guided antibiotic durations for common serious neonatal infections: a collection of non-inferiority meta-analyses.EClinicalMedicine · 2025Article
- Pathogen distribution and antimicrobial resistance among neonatal bloodstream infections in Southeast Asia: results from NeoSEAP, a multicentre retrospective study.The Lancet regional health. Western Pacific · 2025Article
- Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 13 countries.
Funding
Abstract
Neonatal invasive candidiasis (NIC) has significant morbidity and mortality. Reports have shown a different profile of those neonates affected with NIC and of fluconazole-resistant Candida spp. isolates in low- and middle-income countries (LMICs) compared to high-income countries (HICs). We describe the epidemiology, Candida spp. distribution, treatment, and outcomes of neonates with NIC from LMICs enrolled in a global, prospective, longitudinal, observational cohort study (NeoOBS) of hospitalized infants <60 days postnatal age with sepsis (August 2018-February 2021). A total of 127 neonates from 14 hospitals in 8 countries with Candida spp. isolated from blood culture were included. Median gestational age of affected neonates was 30 weeks (IQR: 28-34), and median birth weight was 1270 gr (interquartile range [IQR]: 990-1692). Only a minority had high-risk criteria, such as being born <28 weeks, 19% (24/127), or birth weight <1000 gr, 27% (34/127). The most common Candida species were C. albicans (n = 45, 35%), C. parapsilosis (n = 38, 30%), and Candida auris (n = 18, 14%). The majority of C. albicans isolates were fluconazole susceptible, whereas 59% of C. parapsilosis isolates were fluconazole-resistant. Amphotericin B was the most common antifungal used [74% (78/105)], followed by fluconazole [22% (23/105)]. Death by day 28 post-enrollment was 22% (28/127). To our knowledge, this is the largest multi-country cohort of NIC in LMICs. Most of the neonates would not have been considered at high risk for NIC in HICs. A substantial proportion of isolates was resistant to first choice fluconazole. Understanding the burden of NIC in LMIC is essential to guide future research and treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.